Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosaroxin + Cytarabine in Relapsed/Refractory AML
NCT00541866Phase 2Completed
- Sponsor
- Sunesis Pharmaceuticals, Inc.
- Start
- Oct 2007
- Primary completion
- Feb 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of vosaroxin in acute myeloid leukemia (AML) (2 arms), sponsored by Sunesis Pharmaceuticals, Inc. Primary endpoint: Incidence of Dose-Limiting Toxicity. Started Oct 2007; status: completed.
02
Drugs
vosaroxin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00541866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541866.